471 related articles for article (PubMed ID: 18481391)
41. Adoptive transfer of an anti-MART-1(27-35)-specific CD8+ T cell clone leads to immunoselection of human melanoma antigen-loss variants in SCID mice.
Lozupone F; Rivoltini L; Luciani F; Venditti M; Lugini L; Cova A; Squarcina P; Parmiani G; Belardelli F; Fais S
Eur J Immunol; 2003 Feb; 33(2):556-66. PubMed ID: 12645955
[TBL] [Abstract][Full Text] [Related]
42. Expression of differentiation melanoma-associated antigen genes is associated with favorable disease outcome in advanced-stage melanomas.
Takeuchi H; Kuo C; Morton DL; Wang HJ; Hoon DS
Cancer Res; 2003 Jan; 63(2):441-8. PubMed ID: 12543800
[TBL] [Abstract][Full Text] [Related]
43. Phase I clinical study with multiple peptide vaccines in combination with tetanus toxoid and GM-CSF in advanced-stage HLA-A*0201-positive melanoma patients.
Bins A; Mallo H; Sein J; van den Bogaard C; Nooijen W; Vyth-Dreese F; Nuijen B; de Gast GC; Haanen JB
J Immunother; 2007; 30(2):234-9. PubMed ID: 17471170
[TBL] [Abstract][Full Text] [Related]
44. Adenovirus MART-1-engineered autologous dendritic cell vaccine for metastatic melanoma.
Butterfield LH; Comin-Anduix B; Vujanovic L; Lee Y; Dissette VB; Yang JQ; Vu HT; Seja E; Oseguera DK; Potter DM; Glaspy JA; Economou JS; Ribas A
J Immunother; 2008 Apr; 31(3):294-309. PubMed ID: 18317358
[TBL] [Abstract][Full Text] [Related]
45. A phase I study of an allogeneic cell vaccine (VACCIMEL) with GM-CSF in melanoma patients.
Barrio MM; de Motta PT; Kaplan J; von Euw EM; Bravo AI; Chacón RD; Mordoh J
J Immunother; 2006; 29(4):444-54. PubMed ID: 16799340
[TBL] [Abstract][Full Text] [Related]
46. Melanoma-associated antigen tyrosinase but not Melan-A/MART-1 expression and presentation dissociate during the heat shock response.
Milani V; Frankenberger B; Heinz O; Brandl A; Ruhland S; Issels RD; Noessner E
Int Immunol; 2005 Mar; 17(3):257-68. PubMed ID: 15642953
[TBL] [Abstract][Full Text] [Related]
47. Activation of human melanoma reactive CD8+ T cells by vaccination with an immunogenic peptide analog derived from Melan-A/melanoma antigen recognized by T cells-1.
Ayyoub M; Zippelius A; Pittet MJ; Rimoldi D; Valmori D; Cerottini JC; Romero P; Lejeune F; Liénard D; Speiser DE
Clin Cancer Res; 2003 Feb; 9(2):669-77. PubMed ID: 12576434
[TBL] [Abstract][Full Text] [Related]
48. Immunologic and clinical outcomes of a randomized phase II trial of two multipeptide vaccines for melanoma in the adjuvant setting.
Slingluff CL; Petroni GR; Chianese-Bullock KA; Smolkin ME; Hibbitts S; Murphy C; Johansen N; Grosh WW; Yamshchikov GV; Neese PY; Patterson JW; Fink R; Rehm PK
Clin Cancer Res; 2007 Nov; 13(21):6386-95. PubMed ID: 17975151
[TBL] [Abstract][Full Text] [Related]
49. Tumor antigen-specific FOXP3+ CD4 T cells identified in human metastatic melanoma: peptide vaccination results in selective expansion of Th1-like counterparts.
Jandus C; Bioley G; Dojcinovic D; Derré L; Baitsch L; Wieckowski S; Rufer N; Kwok WW; Tiercy JM; Luescher IF; Speiser DE; Romero P
Cancer Res; 2009 Oct; 69(20):8085-93. PubMed ID: 19808957
[TBL] [Abstract][Full Text] [Related]
50. Molecular tumor markers in the blood: early prediction of disease outcome in melanoma patients treated with a melanoma vaccine.
Wascher RA; Morton DL; Kuo C; Elashoff RM; Wang HJ; Gerami M; Hoon DS
J Clin Oncol; 2003 Jul; 21(13):2558-63. PubMed ID: 12829676
[TBL] [Abstract][Full Text] [Related]
51. The immunodominant HLA-A2-restricted MART-1 epitope is not presented on the surface of many melanoma cell lines.
Sørensen RB; Junker N; Kirkin A; Voigt H; Svane IM; Becker JC; thor Straten P; Andersen MH
Cancer Immunol Immunother; 2009 May; 58(5):665-75. PubMed ID: 18828018
[TBL] [Abstract][Full Text] [Related]
52. Double-blind trial of a polyvalent, shed-antigen, melanoma vaccine.
Bystryn JC; Zeleniuch-Jacquotte A; Oratz R; Shapiro RL; Harris MN; Roses DF
Clin Cancer Res; 2001 Jul; 7(7):1882-7. PubMed ID: 11448900
[TBL] [Abstract][Full Text] [Related]
53. Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase: a phase I trial.
Bergman PJ; McKnight J; Novosad A; Charney S; Farrelly J; Craft D; Wulderk M; Jeffers Y; Sadelain M; Hohenhaus AE; Segal N; Gregor P; Engelhorn M; Riviere I; Houghton AN; Wolchok JD
Clin Cancer Res; 2003 Apr; 9(4):1284-90. PubMed ID: 12684396
[TBL] [Abstract][Full Text] [Related]
54. Generation of a prophylactic melanoma vaccine using whole recombinant yeast expressing MART-1.
Riemann H; Takao J; Shellman YG; Hines WA; Edwards CK; Franzusoff A; Norris DA; Fujita M
Exp Dermatol; 2007 Oct; 16(10):814-22. PubMed ID: 17845213
[TBL] [Abstract][Full Text] [Related]
55. Synthesis of glycocluster-tumor antigenic peptide conjugates for dendritic cell targeting.
Srinivas O; Larrieu P; Duverger E; Boccaccio C; Bousser MT; Monsigny M; Fonteneau JF; Jotereau F; Roche AC
Bioconjug Chem; 2007; 18(5):1547-54. PubMed ID: 17602511
[TBL] [Abstract][Full Text] [Related]
56. A multipeptide vaccine is safe and elicits T-cell responses in participants with advanced stage ovarian cancer.
Chianese-Bullock KA; Irvin WP; Petroni GR; Murphy C; Smolkin M; Olson WC; Coleman E; Boerner SA; Nail CJ; Neese PY; Yuan A; Hogan KT; Slingluff CL
J Immunother; 2008 May; 31(4):420-30. PubMed ID: 18391753
[TBL] [Abstract][Full Text] [Related]
57. Two phase I studies of low dose recombinant human IL-12 with Melan-A and influenza peptides in subjects with advanced malignant melanoma.
Cebon J; Jäger E; Shackleton MJ; Gibbs P; Davis ID; Hopkins W; Gibbs S; Chen Q; Karbach J; Jackson H; MacGregor DP; Sturrock S; Vaughan H; Maraskovsky E; Neumann A; Hoffman E; Sherman ML; Knuth A
Cancer Immun; 2003 Jul; 3():7. PubMed ID: 12862418
[TBL] [Abstract][Full Text] [Related]
58. Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma.
Butterfield LH; Ribas A; Dissette VB; Amarnani SN; Vu HT; Oseguera D; Wang HJ; Elashoff RM; McBride WH; Mukherji B; Cochran AJ; Glaspy JA; Economou JS
Clin Cancer Res; 2003 Mar; 9(3):998-1008. PubMed ID: 12631598
[TBL] [Abstract][Full Text] [Related]
59. Memory and effector CD8 T-cell responses after nanoparticle vaccination of melanoma patients.
Speiser DE; Schwarz K; Baumgaertner P; Manolova V; Devevre E; Sterry W; Walden P; Zippelius A; Conzett KB; Senti G; Voelter V; Cerottini JP; Guggisberg D; Willers J; Geldhof C; Romero P; Kündig T; Knuth A; Dummer R; Trefzer U; Bachmann MF
J Immunother; 2010 Oct; 33(8):848-58. PubMed ID: 20842051
[TBL] [Abstract][Full Text] [Related]
60. Inverse relationship of melanocyte differentiation antigen expression in melanoma tissues and CD8+ cytotoxic-T-cell responses: evidence for immunoselection of antigen-loss variants in vivo.
Jäger E; Ringhoffer M; Karbach J; Arand M; Oesch F; Knuth A
Int J Cancer; 1996 May; 66(4):470-6. PubMed ID: 8635862
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
